Clinical Trials Directory

Trials / Sponsors / QED Therapeutics, a BridgeBio company

QED Therapeutics, a BridgeBio company

Industry · 11 registered clinical trials — 5 currently recruiting.

StatusTrialPhaseStarted
Enrolling By InvitationOpen-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Hypochondroplasia
Phase 22026-04-21
RecruitingInterventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Achondroplasia
Phase 22025-11-19
Enrolling By InvitationAn Interventional Study of Infigratinib in Children With Hypochondroplasia
Hypochondroplasia
Phase 2 / Phase 32025-04-22
RecruitingProspective Clinical Assessment Study in Children With Hypochondroplasia
Hypochondroplasia
—2024-06-05
CompletedA Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Achondroplasia
Phase 32023-11-10
Enrolling By InvitationExtension Study of Infigratinib in Children With Achondroplasia (ACH)
Achondroplasia
Phase 22021-12-06
TerminatedOral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible F
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Phase 32020-03-11
CompletedStudy of Infigratinib in Children With Achondroplasia
Achondroplasia
Phase 22020-03-10
TerminatedPhase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Transloca
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Phase 32019-12-27
CompletedProspective Clinical Assessment Study in Children With Achondroplasia (ACH)
Achondroplasia
—2019-08-12
TerminatedA Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Phase 22014-07-23